




BID = twice daily; SALT = Severity of Alopecia Tool
NOTE: Percentages were based on observed data. *P* values were based on the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo. Missing values were imputed using MI under MAR assumptions.
[1] Responders are subjects with SALT score ≤ 20 .
*****p* value ≤ 0.0001

FIG. 1





FIG. 2



	Deuruxolitinib 8 mg BID (n = 813)	Deuruxolitinib 12 mg BID (n = 662)	Total (N = 1475)
Age (years), Mean (SD)	38.7 (13.10)	38.9 (13.13)	38.8 (13.11)
Sex, n (%)			
Male	275 (33.8)	249 (37.6)	524 (35.5)
Female	538 (66.2)	413 (62.4)	951 (64.5)
Race, n (%)			
American Indian or Alaska Native	4 (0.5)	2 (0.3)	6 (0.4)
Asian	52 (6.4)	43 (6.5)	95 (6.4)
Black or African American	77 (9.5)	58 (8.8)	135 (9.2)
Native Hawaiian or Pacific Islander	5 (0.6)	2 (0.3)	7 (0.5)
White	592 (72.8)	513 (77.5)	1105 (74.9)
Other	21 (2.6)	11 (1.7)	32 (2.2)
Multiple	0	3 (0.5)	3 (0.2)
N/A	62 (7.6)	30 (4.5)	92 (6.2)

FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

FIG. 13A




FIG. 13B




FIG. 13C






FIG. 14A



**** $P < 0.0001$ vs placebo.
¹Responders were defined as patients who were "satisfied" or "very satisfied" on the SPRO. ²Percentages were based on observed data; ³ P values were based on the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near complete) for each treatment group vs placebo. Missing values were imputed using multiple imputation under missing at random assumptions.
BID = twice daily; SPRO = Hair Satisfaction Patient Reported Outcome.

FIG. 14B



**** $P < 0.0001$ vs placebo.
BID = twice daily; SALT = Severity of Alopecia Tool.